###begin article-title 0
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 27 32 <span type="species:ncbi:9606">human</span>
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
###end article-title 0
###begin title 1
Background:
###end title 1
###begin p 2
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
BCL3 is a putative oncogene encoding for a protein belonging to the inhibitory kappaB-family. We experienced that this putative oncogene was a common target gene for growth-promoting cytokines in myeloma cell lines.
###end p 2
###begin title 3
Methods:
###end title 3
###begin p 4
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Gene expression of BCL3 was studied in 351 newly diagnosed myeloma patients, 12 patients with smouldering myeloma, 44 patients with monoclonal gammopathy of undetermined significance and 22 healthy individuals. Smaller material of samples was included for mRNA detection by RT-PCR, protein detection by Western blot and immunohistochemistry, and for cytogenetic studies. A total of eight different myeloma cell lines were studied.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 249 253 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 411 415 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 330 337 <span type="species:ncbi:9606">patient</span>
Bcl-3 was induced in myeloma cell lines by interleukin (IL)-6, IL-21, IL-15, tumor necrosis factor-alpha and IGF-1, and its upregulation was associated with increased proliferation of the cells. In a population of 351 patients, expression levels of BCL3 above 75th percentile were associated with shorter 5-yr survival. When this patient population was divided into subgroups based on molecular classification, BCL3 was significantly increased in a poor risk subgroup characterized by overexpression of cell cycle and proliferation related genes. Intracellular localization of Bcl-3 was dependent on type of stimulus given to the cell.
###end p 6
###begin title 7
Conclusion:
###end title 7
###begin p 8
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
BCL3 is a common target gene for several growth-promoting cytokines in myeloma cells and high expression of BCL3 at the time of diagnosis is associated with poor prognosis of patients with multiple myeloma (MM). These data may indicate a potential oncogenic role for Bcl-3 in MM.
###end p 8
###begin p 9
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 662 666 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 793 799 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 812 818 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 836 840 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 929 930 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 931 932 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 962 966 958 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 1062 1066 1058 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 978 985 <span type="species:ncbi:9606">patient</span>
Myeloma cells are dependent on signals from the bone marrow micro-environment for proliferation and survival (1). Myeloma cell growth factors mediate redundant effects since one growth factor can substitute for another in vitro (2, 3). This observation led us to hypothesize that intracellular signals generated by myeloma growth factors target common genes important for growth and survival of myeloma cells. These genes may represent potential drug targets. Microarray experiments done in our laboratory showed that the myeloma cell growth factors interleukin (IL)-6, IL-21 and tumor necrosis factor (TNF)-alpha all induced expression of the putative oncogene BCL3 in the myeloma cell lines IH-1 and OH-2 (paper in preparation). These data supported previous studies done by Brocke-Heidrich et al. and Tsuyama et al., who showed that BCL3 is upregulated by IL-6 at mRNA level as well as at protein level in myeloma cell lines (4-6). However, the expression of BCL3 in myeloma patient samples has not been studied. Based on this we decided to study the role of BCL3 in primary myeloma cells as well as in myeloma cell lines in more detail.
###end p 9
###begin p 10
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 431 435 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 460 466 460 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 648 652 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 539 544 <span type="species:ncbi:10090">mouse</span>
###xml 615 624 <span type="species:ncbi:10090">nude mice</span>
BCL3 was first identified through its involvement in the t (14;19) (q32;q13) translocation in B-cell chronic lymphocytic leukemia (CLL) (7). Leukemic cells from these patients had increased levels of BCL3 mRNA, leading to the hypothesis that BCL3 is a proto-oncogene contributing to leukemogenesis (8). BCL3 is overexpressed in breast cancers, subtypes of lymphomas and nasopharyngeal carcinomas (9-12). Supporting the notion that BCL3 is an oncogene, Viatour et al. demonstrated that overexpression of BCL3 is sufficient to transform the mouse fibroblast cell line NIH3T3 and induce tumor growth subcutaneously in nude mice (13). Physiologically, BCL3 has been implicated to play a role during B-cell development and as a negative regulator of immune responses (14-16).
###end p 10
###begin p 11
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 97 99 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 101 103 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 271 273 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 417 419 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 578 580 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 582 584 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 585 587 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 620 624 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 726 730 694 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
BCL3 encodes a protein denoted Bcl-3 that is a member of the inhibitory kappaB (IkappaB)-family (17, 18). The IkappaB proteins modulate the DNA-binding activity of nuclear factor-kappaB (NFkappaB), a family of transcription factors involved in apoptosis and cell growth (19). Activation of NFkappaB is implicated as an important mechanism for the development of antiapoptosis and drug resistance in multiple myeloma (20). Depending on context, Bcl-3 either activates or inhibits NFkappaB-dependent gene transcription through interactions with homodimers of NFkappaB p50 or p52 (14, 21-26). We here present evidence that BCL3 is overexpressed in myeloma cells from a subset of myeloma patients, and that the high expression of BCL3 at the time of diagnosis is associated with inferior prognosis. Furthermore, high expression of Bcl-3 in myeloma cell lines induced by growth-promoting cytokines is associated with increased proliferation of the cells. We propose that Bcl-3 contributes to regulation of NFkappaB-dependent gene transcription in myeloma cells, with potential oncogenic consequences.
###end p 11
###begin title 12
Materials and methods
###end title 12
###begin title 13
Cell lines and culture conditions
###end title 13
###begin p 14
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 511 512 511 512 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 729 730 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 61 65 <span type="species:ncbi:162683">Mayo</span>
###xml 609 613 <span type="species:ncbi:9913">calf</span>
The human myeloma cell line ANBL-6 (gift from Dr D. Jelinek, Mayo Clinic, Rochester, MN, USA), IH-1 (3), INA-6 (gift from Dr M. Gramatzki, Erlangen, Germany), JJN-3 (gift from Dr J. Ball, Department of Immunology, University of Birmingham, UK), OH-2 (2), RPMI-8226 and U-266 (both from American Type Culture Collection, Rockville, MD, USA) were cultured as previously described (27). The CAG cell line (gift from Dr J Epstein, Little Rock, AK, USA) was grown in RPMI 1640 (Gibco, Paisley, UK) supplemented with l-glutamine 100 mug/mL, gentamicin 20 mug/mL (referred to as RPMI) and 10% heat inactivated fetal calf serum (FCS; HyClone, Logan, UT, USA). The cells were kept at 37degreesC in a humidified atmosphere containing 5% CO2, and were washed four times in Hanks  balanced salt solution (HBSS; Gibco, Paisley, UK) to deplete them of serum and cytokines before performing experiments.
###end p 14
###begin title 15
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and healthy individuals; separation of CD138+ plasma cells
###end title 15
###begin p 16
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 389 396 <span type="species:ncbi:9606">patient</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
Gene expression profiles (GEP) were studied in plasma cells from 351 patients with newly diagnosed multiple myeloma (MM), 12 patients with smouldering multiple myeloma (SMM), 44 patients with monoclonal gammopathy of undetermined significance (MGUS) and 22 healthy individuals. The patients were recruited from University of Arkansas for Medical Sciences, Little Rock, USA, and the use of patient samples in research studies was approved by the University of Arkansas for Medical Sciences (Little Rock, AR) Institutional Review Board. Details about classification of these patients have been previously described (28, 29).
###end p 16
###begin p 17
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 8 15 <span type="species:ncbi:9606">patient</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
We used patient samples from the Norwegian Research Biobank for multiple myeloma for studies of Bcl-3 expression by RT-PCR (10 patients) immunohistochemistry (18 patients with MM and three patients with plasmocytoma), Western blot (eight patients) and cIg-FISH (19 patients). The Norwegian Research Biobank for multiple myleoma has been approved by the Regional Ethics Committee of Middle Norway and Norwegian Health Authorities. All patients have signed informed consent to store samples in the Biobank and to use samples for research purposes. Separation of plasma cells before GEP was done as previously described (28).
###end p 17
###begin title 18
Cytokines and antibodies
###end title 18
###begin p 19
###xml 378 380 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 773 776 <span type="species:ncbi:9685">Cat</span>
IL-6 was purchased from Biosource (Camarillo, CA, USA). IL-10, IL-15 and insulin-like growth factor (IGF)-1 were from R&D systems (Abingdon, UK). TNF-alpha was from Genetech (South San Francisco, CA, USA), and IL-21 was a gift from R.Holly, ZymoGenetics (Seattle, WA, USA). Hepatocyte growth factor (HGF) was purified from a medium conditioned by JJN-3 as described previously (30). All cytokines except HGF were of recombinant human type. Polyclonal anti-Bcl-3 (sc-185), polyclonal anti-p65 (sc-109) and monoclonal anti-p50 (sc-8414) for Western blotting were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Monoclonal anti-GAPDH and anti-Lamin B used as loading controls on Western blots were purchased from Abcam (ab8245; Cambridge, UK) and Calbiochem (Cat#NA12; Darmstadt, Germany), respectively.
###end p 19
###begin title 20
Preparation of cRNA and microarray hybridization
###end title 20
###begin p 21
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
RNA, cRNA preparation and hybridization to U133 Plus2 GeneChip microarrays (Affymetrix, Santa Clara, CA, USA) were performed as previously described (31).
###end p 21
###begin title 22
Statistical analysis
###end title 22
###begin p 23
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 193 198 193 198 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anova</sc>
###xml 379 383 379 383 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spss</sc>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Gene expression was analyzed as previously described (28, 31). Differences in expression of BCL3 between plasma cells from MM patients and normal plasma cells (NPC) were analyzed using One-Way anova test. Survival distributions were presented with the use of the Kaplan-Meier method and compared with the log-rank test. Statistical tests were performed with the software package spss 12.0 (SPSS, Chicago, IL, USA).
###end p 23
###begin title 24
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
Analysis of BCL3 expression by quantitative real-time PCR (qPCR)
###end title 24
###begin p 25
###xml 397 401 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 474 478 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 580 584 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Plasma cells from 10 patients were isolated with CD138 antibodies conjugated to magnetic beads using a RoboSep (StemCell Technologies, Vancouver, BC, Canada) cell separation device. Total RNA isolated using the MirVanatrade mark miRNA Isolation Kit (Applied Biosystems, Foster City, CA, USA). cDNA was synthesized using Taqman reverse transcriptase reagents from Roche-Applied Biosystems. qPCR of BCL3 was performed using StepOne Real-Time PCR System, (Applied Biosystems). BCL3 TaqMan primer (Hs00180403_m1, Taqman, Gene Expression Assays, Applied Biosystems) was used to detect BCL3 expression. The comparative Ct-method was used for quantization with GAPDH (HS99999905_m1) as housekeeping gene.
###end p 25
###begin title 26
Western blotting
###end title 26
###begin p 27
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 840 841 834 835 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 984 985 972 973 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1258 1259 1239 1240 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1737 1765 1718 1746 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">adobe photoshop elements 4.0</sc>
###xml 66 72 <span type="species:ncbi:9913">bovine</span>
###xml 1435 1446 <span type="species:ncbi:3704">horseradish</span>
Cells (1.2 x 106) were seeded in 3 mL RPMI supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, USA) before Western blotting of whole cell lysates. The ANBL-6, IH-1, INA-6 and OH-2 cell lines were starved overnight before they were stimulated with cytokines as indicated at time point 0 (T0). At this time point, cells that were not stimulated with cytokines were harvested. The viability of these cells as measured by propidium iodide-staining was 60-80%, similar to the viability of cells grown in IL-6 enriched medium. CAG, JJN-3, RPMI-8226 and U-266 were stimulated with IL-6 immediately after seeding or left without cytokines in RPMI with 0.1% BSA for 24 h. After harvesting, dry pellets were kept at -80degreesC until further processing. Pellets were lysed in lysis buffer (10% sodium dodecyl sulfate, 10 mm Tris-HCL, pH 6.8) at 50degreesC using a Hamilton injector, mixed with NuPage LDS sample buffer (Invitrogen, Carlsbad, CA, USA) containing 0.1 m dithiothreitol, and heated for 2 min at 90degreesC. The lysates (40 mug of proteins) were then separated on 10% NuPage Bis-Tris gels (Invitrogen), followed by electrophoretic transfer to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked in 50 mm Tris buffered saline pH 7.5 containing 0.05% Tween 20 and 5% non-fat dried milk (Nestle, Vevey, Switzerland) and incubated with antibodies as indicated. After incubation with horseradish peroxidase-conjugated secondary antibodies (DakoCytomation, Glostrup, Denmark), the proteins were visualized by ECL Western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK), scanned (Canoscan D1250 U25, Canon Europa NV, Amstelveen, The Netherlands) and imported into adobe photoshop elements 4.0 software (Adobe Systems Inc, San Jose, CA, USA) for image acquisition. Cytosol-and nuclear extracts of IH-1 were prepared using Active Motifs nuclear extract kit (Active Motif, CA, USA) according to the manufacturer's protocol. These cells were seeded in RPMI containing 10% FCS and cytokines as indicated for 24 h without previous starvation of cells.
###end p 27
###begin title 28
Thymidine incorporation assays
###end title 28
###begin p 29
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 284 285 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 541 542 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
To measure DNA synthesis, cells were seeded in triplets in 96-well cell culture plates (Corning Inc, Corning, NY, USA) at a density of 2 x 104 cells per well in RPMI supplemented with 0.1% BSA and cytokines as indicated. ANBL-6, IH-1,INA-6 and OH-2 were pulsed with 0.75 muCi methyl-[3H]-thymidine (NEN Life Science products, Boston, MA, USA) after 30 h of stimulation with cytokines and harvested 18 h later using a Micromate 96-well harvester (Packard, Meriden, CT, USA). CAG, JJN-3, RPMI-8226 and U-266 were pulsed with 0.75 muCi methyl-[3H]-thymidine for 4 h after 24 h of stimulation. Beta-radiation was measured with Matrix 96 counter (Packard).
###end p 29
###begin title 30
Immunohistochemistry
###end title 30
###begin p 31
###xml 110 112 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 375 376 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 437 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 462 463 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Sections (4 mum) of formalin-fixed bone marrow biopsies were prepared and visualized as previously described (32). The sections were incubated with a monoclonal antibody specific for Bcl-3 (clone 1E8, Novocastra, Newcastle upon Tyne, UK) at a dilution of 1 : 25. Parallel sections were stained with anti CD138 (Dako, code no. M7228, clone MI 15, dilution 1 : 100). Only CD138+ cells were considered and the biopsies were defined as Bcl3+ when >/=20% of the CD138+ cells was stained.
###end p 31
###begin title 32
###xml 40 47 40 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
Cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg-FISH)
###end title 32
###begin p 33
###xml 192 196 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 845 847 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 432 436 <span type="species:ncbi:9925">goat</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
Cytospin of Lymphoprep-separated (Dynal, Oslo, Norway) bone marrow mononuclear cells from MM patients were fixed in acetic acid/methanol (1:3 v/v, -20degreesC, 40 min) and air-dried. 5 muL of BCL3 split probe (No.Y5411; DakoCytomation) was applied and the slide was sealed with coverslip and rubber cement. Hybridization was done in a Dako Hybridizer according to the manufacturer's protocol. The cells were then incubated with 15% goat serum in phosphate buffered saline. Plasma cells were labeled with AMCA (7-amino-4-methylcoumarin-3-acetic acid)-conjugated anti-human IgG against cytoplasmic kappa/lambda-chains (Vector Laboratories, Burlingame, CA, USA). The slides were air dried in the dark before anti-fade (Vectashield had-set mounting medium without DAPI, Vector Laboratories) was added. The cells were scored as previously described (32). Normal locus was detected as a colocalization of red and green signal, and a split was detected as separate red and green signal.
###end p 33
###begin title 34
Assessment of NFkappaB activity
###end title 34
###begin p 35
###xml 116 118 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
Activation of the NFkappaB family members can be measured by their capacity to bind to consensus DNA binding sites (33). We used the TransAm NFkappaB p65 and p50 transcription Factor Assay Kit (Active Motif, CA, USA) to quantify the DNA binding activity of p50 and p65. The assay was performed according to the manufacturer's protocol. Briefly, IH-1 cells were cultured for 24 h without previous starvation in RPMI containing 10% FCS and cytokines as indicated. Nuclear extracts were prepared and incubated in 96-well plates coated with an immobilized oligonucleotide containing the 5 -GGACTTTCC-3  consensus binding site for NFkappaB. Hybridization to the target oligonucleotide was detected by incubation with primary antibodies specific for p65 of p50, visualized by anti-IgG1-HRP and quantified at 450 nm. Specificity was confirmed by incubating with a wild type consensus oligonucleotide that competed with the substrate for binding to the immobilized oligonucleotide.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Growth promoting cytokines induce Bcl-3 in myeloma cell lines
###end title 37
###begin p 38
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 388 395 388 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1A</xref>
###xml 560 567 556 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1A</xref>
###xml 1094 1101 1086 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1B</xref>
We stimulated the IL-6-dependent myeloma cell lines ANBL-6, IH-1, INA-6 and OH-2 with cytokines known to promote growth of myeloma cells (2, 3, 34-37). The cytokines were given in optimal concentrations for growth. Protein expression of Bcl-3 increased in these cell lines after 4 h of cytokine stimulation compared with baseline level, and increased even more after 24 h of stimulation (Fig. 1A). IL-6, IL-21 and TNF-alpha were the most potent inducers of Bcl-3. Cytokines that induced Bcl-3 also induced proliferation of the corresponding myeloma cell line (Fig. 1A). However, there were a few exceptions from this association. In ANBL-6, TNF-alpha increased the level of Bcl-3 without stimulating proliferation, whereas IGF-1 induced proliferation without increasing Bcl-3 expression. We also tested the effect of IL-6 on Bcl-3 expression in the IL-6 independent cell lines CAG, RPMI-8226, U-266 and JJN-3. Bcl-3 was induced in the cell lines where IL-6 gave a proliferative response. JJN-3 had constitutive expression of Bcl-3, and in this cell line IL-6 had no effect on Bcl-3 expression (Fig. 1B).
###end p 38
###begin p 39
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 361 362 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
Protein expression of Bcl-3 in myeloma cell lines and corresponding cell proliferation after cytokine stimulation. Bcl-3 expression in whole cell lysates and corresponding myeloma cell proliferation. The same cytokine concentrations were used for Western blot as for [3H]-thymidine incorporation assay. Average counts per minute (CPM/AVG) are plotted along the y-axis on graph. Bars represent mean + SD of triplicate wells. (A) IL-6 dependent myeloma cell lines (IH-1, OH-2, ANBL-6, INA-6) were harvested after overnight starvation (T0) or stimulated with cytokines as indicated for 4 and 24 h. (B) IL-6-independent myeloma cell lines (CAG, JJN-3, RPMI-8226, U-266) were stimulated with IL-6 or left unstimulated for 24 h. GAPDH was used as loading control.
###end p 39
###begin title 40
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Expression of BCL3 in CD 138+ bone marrow plasma cells from MM patients is associated with poor outcome
###end title 40
###begin p 41
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 567 568 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 609 613 609 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 680 684 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 812 819 812 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2A</xref>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 931 932 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 991 992 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1026 1030 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 1134 1148 1134 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figs 2B and 2C</xref>
###xml 1239 1241 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
###xml 1183 1191 <span type="species:ncbi:9606">patients</span>
We studied GEP of CD138+ bone marrow plasma cells from 351 newly diagnosed MM patients, 22 healthy individuals, 44 patients with MGUS and 12 patients with SMM. Based on 'present' detection call, BCL3 was present in 229 (65%) of MM plasma cell samples and in 11 (46%) of normal plasma cell samples (NPC; data not shown). By further comparison of BCL3 expression between NPC and primary MMs based on absolute intensity signal, there was no significant difference in BCL3 expression (median 445 (range: 23-2555) in MM plasma cells vs. median 534 (range: 41-970) in NPC, P = 0.7). However, when the expression of BCL3 among NPC, MGUS, SMM, and MM subgroups was compared, the level of BCL3 was significantly increased in one of the gene expression-defined high-risk subgroups, namely the PR (proliferation) subgroup (Fig. 2A) (28). When looking at outcome, Kaplan-Meier analysis revealed 5-yr event-free survival estimates of 37% (EFS, P = 0.0125) and 5-yr overall survival estimates of 42% (OS, P = 0.0030) among 88 patients with BCL3 expression above 75th percentile, compared with 52% and 72% among the other 263 patients respectively (Figs 2B and 2C). Our study population of myeloma patients was uniformly treated with tandem transplants (28).
###end p 41
###begin p 42
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 717 718 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 1150 1154 1150 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 1346 1347 1346 1347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1396 1400 1396 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 1506 1510 1506 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 894 902 <span type="species:ncbi:9606">patients</span>
###xml 1136 1144 <span type="species:ncbi:9606">patients</span>
###xml 1369 1376 <span type="species:ncbi:9606">patient</span>
Expression of BCL3 and its protein in CD138+ MM plasma cells. (A) Box plot of BCL3 expression in NPC and in plasma cells from patients with MGUS, SMM and overt MM. The expression level of BCL3 is in addition shown for subgroups of MM patients based on molecular classification. Sample groups are along the x-axis and the natural log transformed Affymetrix-derived signal is plotted on the y-axis. The top, bottom and middle lines of each box correspond to the 75th percentile (top quartile), 25th percentile (bottom quartile) and 50th percentile (median), respectively. The whiskers extend from the 10th percentile (bottom decile) and 90th percentile (top decile). Open circles denote outliers within each group. The P-value states that BCL3 was significantly increased in the proliferation subgroup (PR) compared with the other subgroups as well as to the NPC, MGUS and SMM groups. MY, all MM patients; LB, low bone disease subgroup; MS, MMSET subgroup; HY, hyperdiploid subgroup; CD-1, CCND1 subgroup: CD-2, CCND3 subgroup: MF, MAF/MAFB subgroup. (B) and (C) Kaplan-Meier 5 yr estimates of EFS and OS showed inferior EFS and OS of MM patients with BCL3 expression levels above 75th percentile(top quartile). (D) Bcl-3 was detected in bone marrow biopsies by immunohistochemistry. The bone marrow biopsy illustrated here had an overall 20% Bcl-3+ plasma cells. (E) MM patient with an unbalanced BCL3 translocation detected by cIg-FISH. The red signal is upstream and the green signal is downstream of the BCL3 gene. Colocalization of the signals represents normal genes, while a single green signal represents an unbalanced translocation.
###end p 42
###begin title 43
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Bcl-3 is detected at mRNA and protein level in plasma cells from MM patients
###end title 43
###begin p 44
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 94 103 94 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Figure S1</xref>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 770 777 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2D</xref>
###xml 836 837 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 905 906 905 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 217 224 <span type="species:ncbi:9606">patient</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
###xml 657 664 <span type="species:ncbi:9606">patient</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
Expression of BCL3 mRNA was studied by qPCR in samples from 10 randomly selected MM patients (Figure S1). All patients expressed BCL3, with six of the patients expressing four times or more the amount compared to the patient with the lowest expression level, confirming the Affymetrix data showing that a subset of MM patients expresses high amounts of BCL3. Expression of Bcl-3 at protein level was examined by two independent methods, immunohistochemistry in bone marrow biopsies and Western blot of purified myeloma cells. Of 18 newly diagnosed MM patients and in biopsies from three plasmocytoma patients, two biopsies (one bone marrow biopsy from a MM patient and one plasmocytoma biopsy) were positive for Bcl-3, with 20% and 40% Bcl-3+plasma cells, respectively (Fig. 2D). In addition, one MM bone marrow biopsy had 5-10% of Bcl3+ plasma cells. When looking at the Bcl-3 protein expression in CD138+ plasma cells from eight myeloma patients, we detected Bcl-3 in seven of eight samples with Western blot (data not shown).
###end p 44
###begin title 45
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
The BCL3 gene is altered in malignant plasma cells from MM patients
###end title 45
###begin p 46
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 363 364 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 448 455 448 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2E</xref>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 365 372 <span type="species:ncbi:9606">patient</span>
To reveal whether alterations in the BCL3 gene locus could explain the upregulation of Bcl-3 in malignant plasma cells from MM patients, we examined bone marrow aspirates from 19 newly diagnosed MM patients using cIg-FISH and a commercial BCL3 split probe. We found that four patients had an extra copy of the BCL3 gene (data not shown). In addition, one t (4;14)+ patient had an unbalanced translocation involving an extra copy of the BCL3 locus (Fig. 2E).
###end p 46
###begin title 47
Intracellular localization of Bcl-3 is dependent on type of stimulus given to the cell
###end title 47
###begin p 48
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 239 246 239 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1A</xref>
###xml 330 337 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3A</xref>
###xml 504 511 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1A</xref>
To be activated, Bcl-3 is translocated to the nucleus of the cells (26). We wanted to study if Bcl-3 is a nuclear protein in myeloma cells. We used IH-1 as a model cell line since Bcl-3 was highly inducible by cytokines in this cell line (Fig. 1A). After stimulation with IL-6, Bcl-3 was detected in the nuclear fraction of IH-1 (Fig. 3A). By contrast, Bcl-3 was detected only in the cytosolic fraction of TNF-alpha-stimulated cells. Both IL-6 and TNF-alpha have a proliferative effect on myeloma cells (Fig. 1A).
###end p 48
###begin p 49
###xml 74 75 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 402 404 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 642 643 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
Intracellular localization of Bcl-3 and activation of NFkappaB p50 and p65. (A) Bcl-3 was detected on Western blot in the nuclear fraction of IL-6-stimulated IH-1 cells, but was absent in the nuclear fraction of TNF-alpha- and unstimulated cells. The NFkappaB proteins p50 and p65 were present in all conditions. GAPDH was used as loading control. Presence of GAPDH in the nucleus is earlier reported (43). Lamin B was used to determine the purity of the extracts. (B) Activation of NFkappaB p50 in nuclear extracts of IH-1 after IL-6 stimulation, and p50 and p65 after TNF-alpha-stimulation. Bars represent mean + SD of duplicate wells. The y-axis denotes optical density (OD) at 450 nm. The experiments were repeated three times.
###end p 49
###begin p 50
###xml 177 179 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 181 183 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 184 186 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 188 190 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 478 485 454 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3A</xref>
###xml 566 573 538 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3B</xref>
Bcl-3 has been shown to associate with homodimers of NFkappaB p50 or p52 in the nucleus and repress DNA-binding of p50/p65, the classical NFkappaB dimer activated by TNF-alpha (14, 21-26, 38). We therefore examined the intracellular localization of NFkappaB p50 and p65 in IH-1 after IL-6 and TNF-alpha stimulation, as well as their DNA-binding capacity under these conditions. We found that both these proteins were present in the nucleus after TNF-alpha and IL-6 stimulation (Fig. 3A). However, while TNF-alpha activated both p65 and p50, IL-6 activated p50 only (Fig. 3B). Hence, after IL-6 stimulation, p50 was activated, and this activation coincided with nuclear presence of Bcl-3. Simultaneously, there was a lack of p65 activation.
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
This work shows for the first time that myeloma cells from MM patients express BCL3 and that high expression of BCL3 at the time of diagnosis is associated with reduced survival. Furthermore, in a comparison of molecularly defined subgroups, BCL3 expression was significantly increased in a high risk subgroup characterized by overexpression of cell cycle-and proliferation-related genes (28). Our data are consistent with the concept that high BCL3 expression is an event associated with poor outcome.
###end p 52
###begin p 53
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 341 343 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 454 456 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
We have not shown that BCL3 is an independent adverse prognostic factor and the exact relevance of elevated expression of BCL3 in myeloma high-risk disease is currently unclear. Interestingly, Annunziata et al. has shown that the high risk subgroup with high expression of BCL3 has a very low average expression of NFkappaB signature genes (39). NFkappaB signature genes are genes that are activated by the classical and/or alternative NFkappaB pathway (39). It is therefore tempting to speculate that the nuclear presence of Bcl-3 as after IL-6 stimulation activates a different set of genes than activation of the classical and/or alternative NFkappaB pathway in myeloma cells.
###end p 53
###begin p 54
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 603 610 <span type="species:ncbi:9606">patient</span>
###xml 863 870 <span type="species:ncbi:9606">patient</span>
The array data was confirmed with qPCR in a material with 10 patients. In another randomly selected material with eight patients with MM, Bcl-3 protein was detected in seven of eight samples by Western blot. We also examined the expression of Bcl-3 at protein level by immunohistochemical staining of biopsies from MM patients and patients with plasmacytoma, and found that 11% (two of 18) of the biopsies stained positive for Bcl-3. This proportion of Bcl-3+ plasma cell malignancies is similar to the proportion of B-cell lymphomas expressing Bcl-3 (6%) (9). The discrepancy between the proportion of patient samples positive for BCL3 at mRNA level and biopsies positive for Bcl-3 at protein level may be caused by lower sensitivity of immunostaining of biopsies, a well-known problem when using immunohistochemistry as detection method. However, the number of patient samples tested was small, and we cannot rule out that there is reduced translation or post-translational modifications.
###end p 54
###begin p 55
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 678 684 678 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 497 504 <span type="species:ncbi:9606">patient</span>
Our data showed that stimulation of myeloma cells with various cytokines well-known to promote proliferation increased Bcl-3 expression. These data indicate that the gene encoding Bcl-3 is indeed a common target gene for growth promoting cytokines in myeloma cells. As growth-promoting cytokines are frequently present in the bone marrow of MM patients, cytokine signaling is a highly possible mechanism for upregulation of Bcl-3 in myeloma cells in vivo. Importantly, and in concordance with the patient data, we found that the induction of Bcl-3 by cytokines was associated with increased proliferation of myeloma cells. However, in line with the results from Brocke-Heidrich et al. (5), we could not show any effect on thymidine incorporation or apoptosis when down regulating Bcl-3 with siRNA in the INA-6 cell line (data not shown). These results are from only one cell line and further studies are needed to clarify the exact role of Bcl-3.
###end p 55
###begin p 56
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
Additional potential mechanisms for upregulation of Bcl-3 in MM patients are gains/amplification of the BCL3 gene, as described in patients with anaplastic large cell lymphoma, or translocations involving chromosome 19, as found in patients with CLL (40, 41). Our studies substantiate that both these mechanism may be active in freshly isolated MM patients cells. The BCL3 gene is located at chromosome 19, a chromosome with frequent trisomy in MM patients having a hyperdiploid tumor (42).
###end p 56
###begin p 57
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYLD</italic>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
In our study, intracellular localization of Bcl-3 was dependent of type of stimulus given to the cell. Nuclear accumulation of Bcl-3, as after IL-6 stimulation, has been shown to be associated with p50/Bcl-3- or p52/Bcl-3 dependent gene activation and subsequent proliferation in CYLD-lacking keratinocytes (26). It is possible that similar mechanisms are active in myeloma cells, and may explain why we observed activation of p50 in IH-1 after IL-6 stimulation.
###end p 57
###begin p 58
###xml 106 110 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
The starting point of this study was our observation that IL-6, IL-21 and TNF-alpha induced expression of BCL3 in the myeloma cell lines OH-2 and IH-1. Our study demonstrates that also the protein, Bcl-3, is produced in cell lines by cytokine stimulation and is associated with increased proliferation of the cells. We show for the first time that Bcl-3 is present in a subset of MM patients, and that the high gene expression at the time of diagnosis is associated with inferior prognosis as demonstrated in a large cohort of newly diagnosed patients. Our results indicate a potential role for Bcl-3 in the development of multiple myeloma, and further studies are needed to clarify this.
###end p 58
###begin p 59
###xml 440 448 <span type="species:ncbi:9606">Children</span>
###xml 455 460 <span type="species:ncbi:9606">Women</span>
This work was supported by grants from the Norwegian Cancer Society (A.T.B., U.M.F., T.B.R.), the Cancer Fund of St. Olavs University Hospital (A.T.B., A.S. M-B., A.W.), Odd Fellow s Research Fund (A.T.B.), NIH grant CA55819 (B.B., J.D.S., F.Z.,) and CA97513 (J.D.S.), and the Lebow Fund to Cure Myeloma. We thank Toril Holien and Randi Rosbak for technical assistance with Western blot; Borgny Ytterhus, Department of Laboratory Medicine, Children s and Women  s Health, Norwegian University of Science and Technology, for technical assistance with immunohistochemistry; and Harald Aarset, Department of Pathology and Molecular Genetic, St. Olavs University Hospital, Trondheim, Norway, for assistance with interpretation of immunohistochemistry.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions
###end article-title 61
###begin article-title 62
###xml 57 62 <span type="species:ncbi:9606">human</span>
TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line
###end article-title 62
###begin article-title 63
###xml 51 56 <span type="species:ncbi:9606">human</span>
Interleukin-21 is a growth and survival factor for human myeloma cells
###end article-title 63
###begin article-title 64
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
###end article-title 64
###begin article-title 65
BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription
###end article-title 65
###begin article-title 66
IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3
###end article-title 66
###begin article-title 67
Identification of a transcriptional unit adjacent to the breakpoint in the 14; 19 translocation of chronic lymphocytic leukemia
###end article-title 67
###begin article-title 68
The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control
###end article-title 68
###begin article-title 69
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases
###end article-title 69
###begin article-title 70
###xml 47 52 <span type="species:ncbi:9606">human</span>
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3
###end article-title 70
###begin article-title 71
Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas
###end article-title 71
###begin article-title 72
Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma
###end article-title 72
###begin article-title 73
GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity
###end article-title 73
###begin article-title 74
Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade
###end article-title 74
###begin article-title 75
Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions
###end article-title 75
###begin article-title 76
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Immunological defects in mice with a targeted disruption in Bcl-3
###end article-title 76
###begin article-title 77
The proto-oncogene bcl-3 encodes an I kappa B protein
###end article-title 77
###begin article-title 78
Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B
###end article-title 78
###begin article-title 79
NF-kappaB in cancer: from innocent bystander to major culprit
###end article-title 79
###begin article-title 80
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications
###end article-title 80
###begin article-title 81
The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers
###end article-title 81
###begin article-title 82
Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo
###end article-title 82
###begin article-title 83
The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites
###end article-title 83
###begin article-title 84
The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers
###end article-title 84
###begin article-title 85
Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4 + T cells
###end article-title 85
###begin article-title 86
Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling
###end article-title 86
###begin article-title 87
###xml 79 84 <span type="species:ncbi:9606">human</span>
Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells
###end article-title 87
###begin article-title 88
The molecular classification of multiple myeloma
###end article-title 88
###begin article-title 89
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
###end article-title 89
###begin article-title 90
###xml 92 97 <span type="species:ncbi:9606">human</span>
Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines
###end article-title 90
###begin article-title 91
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
###end article-title 91
###begin article-title 92
###xml 94 99 <span type="species:ncbi:9606">human</span>
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
###end article-title 92
###begin article-title 93
Development of a sensitive multi-well colorimetric assay for active NFkappaB
###end article-title 93
###begin article-title 94
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma
###end article-title 94
###begin article-title 95
###xml 65 70 <span type="species:ncbi:9606">human</span>
Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells
###end article-title 95
###begin article-title 96
###xml 75 80 <span type="species:ncbi:9606">human</span>
A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth
###end article-title 96
###begin article-title 97
###xml 78 83 <span type="species:ncbi:9606">human</span>
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells
###end article-title 97
###begin article-title 98
###xml 136 141 <span type="species:ncbi:9606">human</span>
The role of the two TNF receptors in proliferation, NF-kappa B activation and discrimination between TNF and LT alpha signalling in the human myeloma cell line OH-2
###end article-title 98
###begin article-title 99
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma
###end article-title 99
###begin article-title 100
BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study
###end article-title 100
###begin article-title 101
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
###end article-title 101
###begin article-title 102
Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma
###end article-title 102
###begin article-title 103
###xml 28 33 <span type="species:ncbi:9606">human</span>
Subcellular localization of human glyceraldehyde-3-phosphate dehydrogenase is independent of its glycolytic function
###end article-title 103
###begin title 104
Supporting Information
###end title 104
###begin p 105
Additional Supporting Information may be found in the online version of this article:
###end p 105
###begin p 106
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1.</bold>
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL3</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Figure S1.BCL3 mRNA expression in samples from 10 MM patients.
###end p 106
###begin p 107
Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
###end p 107

